Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder … Read more
Jyong Biotech Ltd. Ordinary Shares (MENS) - Net Assets
Latest net assets as of June 2025: $-22.47 Million USD
Based on the latest financial reports, Jyong Biotech Ltd. Ordinary Shares (MENS) has net assets worth $-22.47 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($37.67 Million) and total liabilities ($60.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-22.47 Million |
| % of Total Assets | -59.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Jyong Biotech Ltd. Ordinary Shares - Net Assets Trend (2020–2024)
This chart illustrates how Jyong Biotech Ltd. Ordinary Shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jyong Biotech Ltd. Ordinary Shares (2020–2024)
The table below shows the annual net assets of Jyong Biotech Ltd. Ordinary Shares from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-36.52 Million | -7.18% |
| 2023-12-31 | $-34.07 Million | -14.99% |
| 2022-12-31 | $-29.63 Million | -27.04% |
| 2021-12-31 | $-23.32 Million | -21.46% |
| 2020-12-31 | $-19.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jyong Biotech Ltd. Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1824700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $1.12 Million | % |
| Total Equity | $-36.52 Million | 100.00% |
Jyong Biotech Ltd. Ordinary Shares Competitors by Market Cap
The table below lists competitors of Jyong Biotech Ltd. Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MKH Bhd
KLSE:6114
|
$48.51 Million |
|
Imas Makina Sanayi AS
IS:IMASM
|
$48.54 Million |
|
Sanstar Ltd
NSE:SANSTAR
|
$48.55 Million |
|
Prevas AB Series B
LSE:0H2J
|
$48.55 Million |
|
MedPeerInc
PINK:MDPEF
|
$48.50 Million |
|
Melhus Sparebank
OL:MELG
|
$48.50 Million |
|
Soken Chemical & Engineering Co. Ltd
MU:SOQ
|
$48.50 Million |
|
Rorze Systems Corporation
KQ:071280
|
$48.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jyong Biotech Ltd. Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -34,073,000 to -36,519,000, a change of -2,446,000.
- Net loss of 3,019,000 reduced equity.
- Other comprehensive income increased equity by 573,000.
- Other factors decreased equity by 0.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.02 Million | -8.27% |
| Other Comprehensive Income | $573.00K | +1.57% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Jyong Biotech Ltd. Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.27 | $1.80 | x |
| 2021-12-31 | $-0.31 | $1.80 | x |
| 2022-12-31 | $-0.39 | $1.80 | x |
| 2023-12-31 | $-0.45 | $1.80 | x |
| 2024-12-31 | $-0.48 | $1.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jyong Biotech Ltd. Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $4.40K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.87 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.67 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-992.70K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $632.90K |
Industry Comparison
This section compares Jyong Biotech Ltd. Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares (MENS) | $-22.47 Million | 0.00% | N/A | $48.51 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |